Founded in May 2021, InCephalo is a preclinical stage biotech company focused on developing antibodies and other biological treatments for brain cancer. The company's founders, who have diverse backgrounds, aim to make a difference in the lives of those diagnosed with this disease. With a team consisting of academics, a neurosurgeon, a legal expert, and a biotech entrepreneur, InCephalo has attracted renowned neurosurgeons, neuro-oncologists, and regulatory experts to join them. Their primary drug candidate has received EMA ODD and their Compartment Lock technology improves local CNS therapy by retaining biologics in the central nervous system, reducing potential side effects.